Under the Right to Try Act, can a patient with stage II colorectal cancer be prescribed ivermectin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ivermectin Cannot Be Prescribed for Stage II Colorectal Cancer Under the Right to Try Act

Ivermectin is not an appropriate treatment option for stage II colorectal cancer and should not be prescribed for this indication, even under the Right to Try Act. The Right to Try Act specifically requires that investigational drugs have completed Phase I trials and be actively under FDA investigation for the specific condition being treated—criteria that ivermectin does not meet for colorectal cancer.

Why Ivermectin Is Not Appropriate

FDA-Approved Indications

Ivermectin is FDA-approved exclusively for parasitic infections (strongyloidiasis and onchocerciasis) 1. The drug label contains no oncology indications whatsoever, and there are no adequate and well-controlled studies in cancer patients.

Right to Try Act Requirements Not Met

The Right to Try Act requires:

  • Active FDA investigation with an Investigational New Drug (IND) application
  • Completion of Phase I safety trials for the specific indication
  • Ongoing clinical development for that condition

Ivermectin has none of these for colorectal cancer. While preclinical studies show potential anticancer effects 2, 3, 4, there are no Phase I, II, or III clinical trials in humans with colorectal cancer, creating what experts describe as a "critical translational gap between preclinical results and practical clinical application" 5.

Evidence-Based Treatment for Stage II Colorectal Cancer

Standard of Care

According to the 2022 ASCO guidelines 6:

For most stage II colon cancer patients:

  • Adjuvant chemotherapy should NOT routinely be offered (strong recommendation, moderate evidence quality) 6
  • Surgery alone provides 68%-83% five-year disease-free survival 6

For high-risk stage II patients (T4 tumors, <12 lymph nodes sampled, perineural/lymphovascular invasion, poor differentiation, obstruction, perforation, high-grade tumor budding):

  • Fluoropyrimidine-based adjuvant chemotherapy may be offered after shared decision-making 6
  • Oxaliplatin addition is not routinely recommended but may be considered 6

Established Treatment Options

The NCCN guidelines 7 outline proven subsequent-line therapies for metastatic disease, including:

  • Checkpoint inhibitors (pembrolizumab, nivolumab) for MMR-deficient tumors
  • Targeted therapies (larotrectinib, entrectinib) for NTRK fusion-positive disease
  • Regorafenib for refractory disease

None of these guidelines mention ivermectin as a treatment option.

Critical Safety and Ethical Concerns

Lack of Human Cancer Data

The most recent comprehensive review 5 from 2025 explicitly states: "Clinical evidence in humans is limited, with no large-scale randomized controlled trials (RCTs) confirming therapeutic benefits" for cancer treatment. The review warns that "observational studies and case reports highlight the risks of self-medication driven by social media touting Ivermectin's unproven cancer benefits, which can lead to toxicity in oncology patients."

Preclinical Evidence Is Insufficient

While laboratory studies show ivermectin can inhibit colorectal cancer cell growth through ROS-mediated apoptosis 2 and animal studies demonstrate some efficacy 3, preclinical data cannot substitute for human clinical trials. Even synergistic combinations with other agents 4 remain purely experimental.

Risk of Forgoing Proven Therapy

The most serious concern is that pursuing unproven treatments may lead patients to delay or refuse evidence-based interventions. For stage II colorectal cancer, this means potentially missing the window for curative surgery or appropriate adjuvant chemotherapy in high-risk cases.

Common Pitfalls to Avoid

  1. Confusing Right to Try with compassionate use: Right to Try has specific legal requirements that ivermectin does not meet for cancer
  2. Overinterpreting preclinical data: Laboratory and animal studies do not predict human efficacy or safety
  3. Social media misinformation: Patients may encounter unsubstantiated claims about ivermectin's cancer benefits 5
  4. Assuming "safe for parasites = safe for cancer": Dosing, duration, and drug interactions differ substantially between indications

Appropriate Clinical Response

Healthcare providers should:

  • Clearly explain that ivermectin is not an evidence-based cancer treatment
  • Discuss the proven treatment options outlined in ASCO guidelines 6
  • For high-risk stage II patients, engage in shared decision-making about adjuvant chemotherapy
  • Direct patients interested in investigational therapies toward legitimate clinical trials
  • Document the discussion thoroughly to protect both patient and provider

The conversation should emphasize that while research into drug repurposing is valuable, patients deserve treatments with established efficacy and safety profiles for their specific cancer type and stage.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.